**Author details**

Alice Barros Câmara Federal University of Rio Grande do Norte, Natal, Brazil

\*Address all correspondence to: alicecamara@hotmail.com

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**119**

*Alzheimer's Disease Neuroprotection: Associated Receptors*

pathologies and cognitive deficits. Acta Neuropathologica. 2017;**134**(5):749-767

[9] Hugon J, Paquet C. Could ryanodine receptor dysfunction be linked to PKR brain accumulations in Alzheimer's disease? Medical Hypotheses.

[10] Shetty AK, Bates A. Potential of GABA-ergic cell therapy for schizophrenia, neuropathic pain, and Alzheimer's and Parkinson's diseases. Brain Research. 2016;**1638**:74-87

[11] Sanchez-Mejias E, Nuñez-Diaz C, Sanchez-Varo R, Gomez-Arboledas A,

Valenzuela JJ, et al. Distinct diseasesensitive GABAergic neurons in the perirhinal cortex of Alzheimer's mice and patients. Brain Pathology.

[12] Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies.

[13] Yan SS, Chen D, Yan S, Guo L, Chen JX. RAGE is a key cellular target for Aβ-induced perturbation in Alzheimer's disease. Frontiers in Bioscience (Scholar Edition).

[14] Galasko D, Bell J, Mancuso JY, Kupiec JW, Sabbagh MN, van Dyck C, et al. Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease. Neurology.

[15] Etchegoyen M, Nobile MH, Baez F, Posesorski B, González J, Lago N, et al. Metabolic syndrome and neuroprotection. Frontiers in

[16] Littlejohns TJ, Henley WE, Lang IA, Annweiler C, Beauchet O, Chaves PH, et al. Vitamin D and the

Neuroscience. 2018;**12**:196

2014;**82**(17):1536-1542

Cell. 2012;**148**(6):1204-1222

Garcia-Leon JA, Fernandez-

2019;**30**(2):345-363

2012;**4**:240

2018;**113**:45-45

*DOI: http://dx.doi.org/10.5772/intechopen.91918*

[1] Lombardo S, Maskos U. Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment. Neuropharmacology.

[2] Ferreira-Vieira TH, Guimaraes MI, Silva RF, Ribeiro MF. Alzheimer's disease: Targeting the cholinergic system. Current Neuropharmacology.

[3] Verma S, Kumar A, Tripathi T, Kumar A. Muscarinic and nicotinic acetylcholine receptor agonists: Current scenario in Alzheimer's disease therapy. Journal of Pharmacy and Pharmacology.

[4] Li KX, Sun Q, Wei LL, Du GH, Huang X, Wang JK. ERα gene promoter methylation in cognitive function and quality of life of patients with Alzheimer disease. Journal of Geriatric Psychiatry and Neurology.

[5] Cui J, Shen Y, Li R. Estrogen synthesis and signaling pathways during aging: From periphery to brain. Trends in Molecular Medicine.

[6] Coman L, Păunescu H, Catană R, Coman LI, Voiculescu Ş, Coman OA. Alzheimer's DiseAse–estrogens AnD selective estrogen receptor moDulAtors, frienDs or foes? Acta Endocrinologica

**References**

2015;**96**:255-262

2016;**14**(1):101-115

2018;**70**(8):985-993

2019;**32**(4):221-228

2013;**19**(3):197-209

(Bucharest). 2017;**13**(1):77

2018;**21**(9):841-848

[7] Câmara AB, de Souza ID, Dalmolin RJS. Sunlight incidence, vitamin D deficiency, and Alzheimer's disease. Journal of Medicinal Food.

[8] Lacampagne A, Liu X, Reiken S, Bussiere R, Meli AC, Lauritzen I, et al. Post-translational remodeling of ryanodine receptor induces calcium leak leading to Alzheimer's disease-like *Alzheimer's Disease Neuroprotection: Associated Receptors DOI: http://dx.doi.org/10.5772/intechopen.91918*
